Summary
McKesson Corporation (MCK) reported strong financial performance for the fiscal year ended March 31, 2026, with revenues increasing by 12% to $403.4 billion and diluted earnings per share rising significantly to $38.38. This growth was driven by solid performance across its business segments, particularly in North American Pharmaceutical and Oncology & Multispecialty. The company also actively managed its capital, returning $5.1 billion to shareholders through share repurchases and dividends, and raised its quarterly dividend. Strategically, McKesson is advancing its business model through significant acquisitions in the Oncology & Multispecialty segment, including PRISM Vision and Core Ventures. Concurrently, the company announced its intention to separate its Medical-Surgical Solutions segment, entering into an agreement for Apollo Funds to acquire a minority interest, signaling a focused approach on core healthcare services. The company also reported no goodwill impairment and continued to manage its operational efficiencies through ongoing restructuring initiatives.
Key Highlights
- 1Revenues increased by 12% year-over-year to $403.4 billion.
- 2Diluted earnings per share saw a substantial increase to $38.38 from $25.72 in the prior year.
- 3Returned $5.1 billion to shareholders via $4.8 billion in stock repurchases and $381 million in dividends.
- 4Completed significant acquisitions in the Oncology & Multispecialty segment: PRISM Vision for $875 million and Core Ventures for $2.5 billion.
- 5Announced plans to separate the Medical-Surgical Solutions segment, with a minority stake sale to Apollo Funds for $1.25 billion.
- 6No goodwill impairment was recorded in fiscal year 2026, indicating stable value of acquired businesses.
- 7Continued investment in operational efficiencies through restructuring charges, with $170 million recorded in fiscal 2026.